Key result
Atherosclerosis and diabetes linked to lower intraplatelet PF4 and greater plasma PF4 release following IV heparin.
Why the study?
Does the intraplatelet level of PF4 and the heparin-mobilisable pool of PF4 differ between patients with atherosclerosis or diabetes and healthy controls?
Case-Control
Does the intraplatelet level of PF4 and the heparin-mobilisable pool of PF4 differ between patients with atherosclerosis or diabetes and healthy controls?
Patients with atherosclerosis and diabetes have altered platelet PF4 content and an exaggerated release of PF4 in response to heparin compared to controls.
Answers are grounded in this paper and cite their sources.
May affect heparin responses in atherosclerosis and diabetes; leaves open clinical relevance for dosing or events.
Some patients with clinical evidence of atherosclerosis and others with diabetes were compared with appropriate controls. The intraplatelet level of platelet factor 4 (PF4) was significantly decreased in the arteriopaths and was lower in the diabetics when compared with controls. Patients with transient ischaemic attacks and stroke have even lower values. Intravenous heparin liberates large amounts of PF4 from an unknown reservoir, perhaps the endothelium, into the plasma. Arteriopaths liberated significantly more PF4 than the controls and the diabetics most. If a second heparin injection is given 24 hr after the first, the resultant plasma PF4 level was on average half that achieved after the first injection and again the patients had higher levels than the controls. Thus the reservoir originally "emptied" of PF4 by the heparin had been partially refilled in 24 hr and the reservoir in the atherosclerotic patients then contained more than the controls. Patients with atherosclerosis and especially diabetics differ from controls in the PF4 content of their platelets and in their response to heparin and in the rate of refill of the "heparin-mobilisable pool of PF4".
No takes yet. Share an insight, caveat, or question.
O’Brien et al. (1984) conducted a case-control in Atherosclerosis and diabetes. Atherosclerosis and diabetes vs. Controls was evaluated on Intraplatelet level of platelet factor 4 (PF4) and heparin-mobilisable pool of PF4. Patients with atherosclerosis and diabetes had significantly decreased intraplatelet PF4 levels and liberated more PF4 into plasma following intravenous heparin compared to controls.
Synapse has enriched 10 related papers. Consider them for comparative context: